Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06841237

Randomized Controlled Trial on the Efficacy and Safety of Xiang Lei Ointment in Diabetic-related Ulcer Management

Diabetes is one of the major chronic diseases. Diabetic ulcers are important adverse outcomes of diabetes. Approximately 80% of lower - limb amputations are caused by diabetic foot ulcers, which are the main causes of disability and death among patients. Moreover, it places a huge burden on the medical insurance system. Currently, there are western medicine treatment guidelines for diabetic foot, yet the clinical efficacy is less than satisfactory. The amputation rate caused by diabetic foot ulcers continues to rise every year. There is an urgent clinical need for novel and effective intervention measures to address this disease.

Macrophages are important cells involved in the inflammatory and proliferative phases of wounds, playing a crucial role in wound repair and reconstruction. Diabetes can cause wounds to remain in the pro - inflammatory stage continuously, leading to the aggregation of M1 macrophages and preventing their timely transformation into the pro - proliferative and repair stage. As a result, wounds exhibit persistent chronic inflammation and delayed tissue proliferation or remodeling.

Xianglei Tangzu Ointment is a natural medicine approved for marketing by the National Medical Products Administration in November 2023. Its ingredients include Pogostemon cablin extract and asiaticoside. Research shows that the plant components in Xianglei Tangzu Ointment can promote the transformation of M1 macrophages into M2 macrophages, thereby reducing the inflammatory response and accelerating the proliferative repair of diabetic wounds. It has achieved certain curative effects in the clinical treatment of promoting wound healing. In order to use Xianglei Tangzu Ointment more precisely, accumulate clinical evidence - based medicine evidence, and explore the effectiveness and safety of Xianglei Tangzu Ointment in treating diabetic ulcers under the guidance of the chronic wound staging theory, clinical evidence - based medicine evidence needs to be obtained.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Peking University 3rd Hospital

Beijing, Beijing Municipality, 100191, China

Location status: Recruiting

Location contact

Li Yunfeng, MD

SUB_INVESTIGATOR

Zhang Long, MD

CONTACT

[email protected]

82266699 ext. 010

Zhang Long, MD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • a confirmed diagnosis of type 1 or type 2 diabetes mellitus that meets the standard World Health Organization definition, with blood glucose controlled prior to enrolment and a glycated haemoglobin HbA1c level of less than 10%;
  • the type of wound is an ulcer;
  • the wound etiology is diabetic, mainly abnormalities in blood glucose, resulting in poor or prolonged healing and requiring standard wound therapy;
  • the staging of the wound is in the granulation phase;
  • voluntary participation in the study and signing of an informed consent form.

Exclusion criteria

  • acute heart attack, heart failure, hepatitis, shock, expiratory failure and other serious diseases that have not been corrected;
  • uncontrolled blood glucose, fasting blood glucose > 15 mmol/L and glycated haemoglobin > 12%;
  • active bleeding in the wound, which does not allow the implementation of the conventional basic treatment plan;
  • serum albumin < 20 g/L; haemoglobin < 60 g/L; platelets < 50 x 109/L;
  • a state of disseminated infection that is being or will be treated with antibiotics
  • patients with advanced malignant tumours;
  • active autoimmune disease;
  • previous allergy to topical human granulocyte macrophage stimulating factor gel (Jinfuning);
  • inability of the patient to co-operate or mental disorder;
  • in the judgement of the investigator, the subject has a clearly irremovable cause of wound healing, is unsuitable for the study or is unable to comply with the requirements of the study.

Treatment and study plan

Xiang Lei Ointment plus Clinical standard treatment protocols

Other

A therapy for chronic wound healing

Clinical standard treatment protocols

Other

A therapy for chronic wound healing

Primary outcomes

  1. wound area reduction rate

    Time frame: From enrollment to the end of treatment at 2 weeks

    Pre-treatment area minus post-treatment area, then divided by pre-treatment area

Secondary outcomes

  1. wound healing rate

    Time frame: From enrollment to the end of treatment at 3 weeks

    Percentage of healed wounds to total cases by D21

  2. Granulation tissue status

    Time frame: From enrollment to the end of treatment at 3 weeks

    They were classified as healthy granulation, inflammatory granulation, infected granulation, oedematous granulation, and aged granulation. D0/D14/D21, wound granulation tissue status was recorded separately

  3. wound infection control

    Time frame: From enrollment to the end of treatment at 3 weeks

    0 points for no infection, 1 point for reduction of localised infection; 2 points for maintenance or exacerbation of localised infection; 3 points for disseminated infection; record D0/D14/D21, the status of the wound infection and record the scoring results respectively

Sponsors and collaborators

Lead sponsor

Peking University Third Hospital

Other

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Feb 24, 2025
Registry last updated
Mar 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.